- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Paroxysmal nocturnal haemoglobinuria
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 676KB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 128KB)
Pegcetacoplan – July 2022
Pegcetacoplan: Solution for subcutaneous infusion 1,080 mg in 20 mL; Empaveli™
Last updated
28 October 2022